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Abstract We have investigated the structure of the glibencla-
mide binding site of pancreatic L-cell ATP-sensitive potassium
(KATP) channels. KATP channels are a complex of four pore-
forming Kir6.2 subunits and four sulfonylurea receptor (SUR1)
subunits. SUR1 (ABCC8) belongs to the ATP binding cassette
family of proteins and has two nucleotide binding domains
(NBD1 and NBD2) and 17 putative transmembrane (TM)
sequences. Co-expression in a baculovirus expression system of
two parts of SUR1 between NBD1 and TM12 leads to
restoration of glibenclamide binding activity, whereas expression
of either individual N- or C-terminal part alone gave no
glibenclamide binding activity, confirming a bivalent structure
of the glibenclamide binding site. By using N-terminally
truncated recombinant proteins we have shown that CL3 ^ the
cytosolic loop between TM5 and TM6 ^ plays a key role in
formation of the N-terminal component of the glibenclamide
binding site. Analysis of deletion variants of the C-terminal part
of SUR1 showed that CL8 ^ the cytosolic loop between TM15
and TM16 ^ is the only determinant for the C-terminal
component of the glibenclamide binding site. We suggest that
in SUR1 in the native KATP channel close proximity of CL3
and CL8 leads to formation of the glibenclamide binding
site. ß 2001 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
The pancreatic L-cell ATP-sensitive potassium (KATP) chan-
nel [1] couples changes in plasma glucose concentration to
insulin secretion [2]. The KATP channel is also the site of
action of the sulfonylurea drugs used to treat type 2 diabetes,
and also of diazoxide, which inhibits insulin secretion and is
used to treat insulinoma and neonatal hyperinsulinemia [3,4].
Regulation of KATP channels in response to an elevation of
blood glucose occurs via increased metabolism of the sugar
within the L-cell and a consequent rise in intracellular [ATP]/
[ADP] ratio [5]. Closure of KATP channels in response to
sulfonylureas and opening of the channels by diazoxide in-
volve direct binding of the drugs to the channel [6].
The L-cell KATP channel contains two subunits, Kir6.2, an
inwardly rectifying K-channel which forms the pore, and
SUR1 which contains the binding sites for sulfonylureas and
diazoxide and functions as a channel regulator [7^9]. There is
evidence for an octameric structure with the active channel
containing four molecules each of Kir6.2 and SUR1 [10,11].
Kir6.2 mediates the inhibitory e¡ect of ATP on channel ac-
tivity [12,13] while SUR1 is responsible for the stimulatory
e¡ect of MgADP and K-channel openers [14] and inhibition
by sulfonylureas [15]. Hydropathy plots and comparison with
related members of the ATP binding cassette (ABC) protein
family suggest that SUR1 contains an N-terminal hydropho-
bic region (TMD0) containing ¢ve transmembrane (TM) heli-
ces, and two repeats of six TM helices (TMD1 and TMD2);
TMD1 and TMD2 are both followed by large cytosolic loops
[16]. SUR1 is a member of the ABC superfamily and there is
evidence that the two large cytosolic loops, which each con-
tain a Walker A and Walker B motif [17], are nucleotide
binding domains (NBDs) [18^20].
Several studies have investigated the regions of Kir6.2 and
SUR1 which interact to form the native regulated channel.
There is evidence from photoa⁄nity labelling [10] and immu-
noprecipitation [21] for close association between Kir6.2 and
SUR1. The C-terminus of Kir6.2 has been shown to be in-
volved in interaction with SUR1 [22] and the ¢rst TM se-
quence and the N-terminal region have been implicated in
channel assembly [23]. Both N- and C-termini of Kir6.2 co-
operate to form the ATP binding site [24]. The cytosolic loop
(CL8) between TMs 15 and 16 of SUR1 has been implicated
in glibenclamide binding [25,26]. Two distinct regions of
TMD2 ^ part of the cytosolic loops between TM13/TM14
and TMTM16/17 ^ have been implicated in binding K-chan-
nel openers [27].
We have previously shown functional expression of KATP
channels in Spodoptera frugiperda insect cells using baculovi-
rus [28]. The properties of the KATP channels expressed in
insect cells did not di¡er signi¢cantly from those of the native
L-cell channel. However, the baculovirus expression system
has the advantage that SUR1 and Kir6.2 can be expressed
individually at the cell membrane, unlike mammalian cells
in which co-expression of both proteins is required for e⁄-
cient targeting [9,29,30]. We have also shown that when SUR1
is divided in two co-expression in the baculovirus system of
the two individual half-molecules leads to expression of gli-
benclamide binding activity, whereas expression of either in-
dividual N- or C-terminal half-molecule shows no glibencla-
mide binding activity [26]. These observations con¢rmed the
involvement of two separate regions of SUR1 in formation of
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the glibenclamide binding site. In the present study we have
examined which structural fragments of SUR1 are required
for glibenclamide binding. We propose a model for the struc-
tural organisation of the glibenclamide binding site of SUR1.
2. Materials and methods
2.1. Cells and viruses
S. frugiperda (Sf21) cells and baculoviruses were maintained as
previously described [26,28].
2.2. Construction of plasmid DNAs and recombinant baculoviruses
Construction of transfer vectors pAcSUR1H, pAcNSUR2 and
pAcCSUR2 containing DNA fragments encoding rat SUR1 [7] under
control of the polyhedrin promoter in the pAcYM1 vector and cor-
responding baculoviruses was previously described [1]. pAcNSUR21
and pAcNSUR22 transfer vectors were obtained by cloning in pA-
cYM1 a PCR copy of SUR1 corresponding to amino acid (aa) se-
quences 207^984 and 295^984 respectively. Both transfer vectors con-
tain after the coding region a BamHI site and sequence encoding
6UHis. PCR copies of the gfp gene were cloned in the BamHI sites
of pAcNSUR21 and pAcNSUR22 to construct pAcNSUR21G and
pAcNSUR22G respectively. pAcSUR1tr, pAcSUR1-17, pAcSUR1-16
and pAcSUR1-16a transfer vectors were obtained by cloning in pAc-
Cas1 PCR copies of SUR1 corresponding to aa sequences 55^1299,
55^1274, 55^1246 and 55^1182 respectively (pAcCas1 contains the
portion of the SUR1 gene encoding aa 1^55, a multicloning site
and a His6 tag [1]). pAcCSUR3tr, pAcCSUR3-17, pAcCSUR3-16
and pAcCSUR3atr transfer vectors were obtained by cloning in pA-
cYM1 PCR copies of SUR1 corresponding to aa sequences 1093^
1299, 1093^1274, 1093^1246 and 1135^1299 respectively and a His6
tag. pAcSURtr1 and pAcSURtr2 transfer vectors were obtained by
cloning in pAcYM1 a PCR copy of SUR1 corresponding to aa se-
quences 207^1299 and 295^1299 respectively. Deletion variants of
pAcSURtr1 transfer vector were obtained by cloning corresponding
PCR products in pAcYM1. The resulting pAcSURtr1v6/7, pAc-
SURtr1v7/8, pAcSURtr1v8/9, pAcSURtr1v9/10, pAcSURtr1v10/11
transfer vectors have deletions corresponding to aa 295^397, 335^
457, 398^526, 458^553, 527^629 respectively. PCR products were ob-
tained by fusion PCR and contained a sequence encoding spacer Ser-
Ala-Ser-Ala-Ser-Ala instead of the deleted region. All PCR products
contain a sequence encoding a His6 tag at the 3P-end. The same
procedure was used for constructing pAcNSUR21v9/10 transfer vec-
tor (aa 207^1125 with deletion of aa 458^553). Transfer vectors were
used for co-transfection of Sf9 cells together with Autographa califor-
nica nuclear polyhedrosis virus DNA (AcNPV PAK6) [23]. Recombi-
nant baculoviruses AcNPVNSUR21, AcNPVNSUR22, AcNPVN-
SUR21G, AcNPVNSUR22G, AcNPVNSUR21v9/10, AcNPV-
SUR1tr, AcNPVSUR1-17, AcNPVSUR1-16, AcNPVSUR1-17,
AcNPVSUR1-16, AcNPVSUR1tr1, AcNPVSUR1tr2, AcNPV-
SUR1tr1v6/7, AcNPVSUR1tr1v7/8, AcNPVSUR1tr1v8/9, AcNPV-
SUR1tr1v9/10, AcNPVSUR1tr1v10/11 were obtained from the cor-
responding transfer vectors, three times plaque-puri¢ed and used for
infection of Sf21 cells.
2.3. [3H]Glibenclamide binding
Sf21 cells resuspended at a density of 5U105 cells/ml in TC100 were
incubated at room temperature (RT) for 30 min with di¡erent con-
centrations of [3H]glibenclamide (0.2^10 nM) in a ¢nal volume of 400
Wl. The incubation was stopped by rapid separation on Whatman GF/
C ¢lters soaked in phosphate-bu¡ered saline (PBS) for 30 min before-
hand. After washing the ¢lters, speci¢c binding was determined and
the dissociation constant, Kd, and the number of glibenclamide bind-
ing sites per cell (Bmax) were estimated as previously described [31].
2.4. SDS^PAGE and immunoblotting
SDS^PAGE and immunoblotting were performed as previously de-
scribed [25]. Anti-His6 tag antibodies (Penta-His, Qiagen) and alkaline
phosphatase conjugated with anti-mouse antibody were used for de-
tection of His-tagged proteins. Rabbit polyclonal anti-NBD1 antisera
(dilution 1:200 000) and alkaline phosphatase conjugated with anti-
rabbit antibody were used for detection of recombinant proteins that
contained NBD1. Anti-NBD1 antisera were obtained after immunisa-
tion of rabbits with puri¢ed NBD1 expressed in Escherichia coli [1].
2.5. Fluorescence microscopy
Insect cells expressing green £uorescent protein (GFP) were grown
on cover slips and viewed with a Leitz DMIRB £uorescent micro-
scope (Leica Microscopie und Systeme GmbH). Ionvision III software
was used for analysing images.
3. Results
3.1. Generation of recombinant proteins
Fig. 1 illustrates the predicted topology of SUR1 and the
regions of SUR1 expressed by vectors used in this study. The
NH2-proximal half-molecule designated NSUR2, which con-
tains the ¢rst two sets of putative TM domains (TMD0 and
TMD1) plus NBD1, was described before [26]. For the
present study we constructed truncated NH2-proximal half-
molecules in which TMD0 (NSUR21) or TMD0 together
with the cytosolic loop (CL3) between TMD0 and TMD1
(NSUR22) were deleted. Both NSUR21 and NSUR22 contain
no arti¢cial leader sequences. It was therefore essential to
establish that these variants were inserted into the plasma
membrane. For this purpose we produced variants of both
these proteins containing GFP at the COOH end (NSUR21G
and NSUR22G). A deletion variant of NSUR21 ^
NSUR21v9/10 ^ without TM9 and TM10 was also con-
structed. We also constructed further truncated and deleted
variants of SUR1. Since we have previously shown that dele-
tion of the second NBD (NBD2) has no signi¢cant e¡ect on
glibenclamide binding [26], NBD2 was omitted from con-
structs described below. We produced three truncated SUR1
constructs : SUR1tr ^ containing intact NH2 end of SUR1;
SUR1tr1 ^ with deletion of TMD0; and SUR1tr2 where
TMD0 was deleted together with the cytosolic loop (CL3)
between TMD0 and TMD1. Deletion variants of SUR1tr1
were also produced. These recombinant proteins contained
the spacer sequence Ser-Ala-Ser-Ala-Ser-Ala instead of the
two deleted TM domains. Five possible mutants with deletion
of two adjacent TM domains from TMD1 were obtained ^
SUR1tr1v6/7, SUR1tr1v7/8, SUR1tr1v8/9, SUR1tr1v9/10,
SUR1tr1v10/11, with deletion of TM6/TM7, TM7/TM8,
TM8/TM9, TM9/TM10, TM10/TM11 respectively. All re-
combinant proteins were designed to contain a His6 tag
that, as we have shown previously [31], does not interfere
with SUR1 assembly and function. Recombinant proteins de-
scribed above contain NBD1 and we therefore used rabbit
polyclonal anti-NBD1 antibodies for detection. Fig. 2 shows
Western blots of Sf21 insect cells expressing the recombinant
proteins. The positions of the main bands on the Western blot
correspond to those predicted from aa sequences.
COOH-proximal half-molecules designated CSUR2 (which
contains the last six putative TM helices (TMD2) plus NBD2)
and CSUR3 (which contains cytoplasmic loop CL7, the last
four putative TM helices from TMD2 plus NBD2) were de-
scribed before [26]. Further deletion variants of CSUR3 were
produced for the present study: CSUR3tr ^ with deletion of
NBD2; CSUR3-17 ^ with deletion of NBD2 and TM17;
CSUR3-16 ^ with deletion of NBD2, TM16 and TM17;
CSUR3atr ^ with deletion of CL7 and NBD2. All recombi-
nant proteins were designed to contain a His6 tag and were
detected by Western blot with anti-His6 tag antibodies (data
not shown). We also made similar deletions of the whole
SUR1 molecule in order to distinguish e¡ects originating
from disturbing molecular assembly and those resulting
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from destruction of the glibenclamide binding site : SUR1-17 ^
with deletion of NBD2 and TM17; SUR1-16 ^ with deletion
of NBD2; TM16 and TM17; and SUR1-16a ^ with deletion
of CL8, TM16, TM17 and NBD2.
3.2. Expression at the plasma membrane of
SUR1 half-molecules
Since neither NSUR21 nor NSUR22 contains an arti¢cial
leader sequence we produced variants of these proteins con-
taining GFP at the COOH end (NSUR21G and NSUR22G)
to prove plasma membrane localisation of the corresponding
proteins. GFP was used as marker for investigation of re-
combinant protein localisation. Fluorescence microscopy of
Sf9 cells expressing recombinant proteins is shown in Fig. 3.
GFP itself (Fig. 3A) was randomly distributed inside the in-
sect cell and did not bind to the plasma membrane. Fig. 3B,C
shows that NBD21G as well as NBD22G were both expressed
at the plasma membrane of Sf9 insect cells infected with the
corresponding recombinant baculovirus. These data show that
even without leader sequence truncated variants of SUR1
possess plasma membrane insertion abilities.
3.3. Glibenclamide binding to insect cells expressing KATP
channel recombinant proteins
In order to characterise glibenclamide binding of di¡erent
recombinant proteins we measured glibenclamide binding ac-
tivity at di¡erent concentrations of glibenclamide and esti-
mated the binding a⁄nity, Kd and number of glibenclamide
binding sites, Bmax. Estimated binding constants and number
of binding sites per cell are shown in Table 1. It can be seen
that despite varying values of Bmax, there are no signi¢cant
di¡erences in Kd between di¡erent expressed proteins. All
binding constants are in the range 1.22^1.92 nM, similar to
that for binding of glibenclamide to intact SUR1, 1.81 nM
Fig. 1. Predicted topology of SUR1 and design of the recombinant proteins containing regions of SUR1 used in this study. Membrane topolo-
gies are based on [16]. Black boxes indicate the SUR1 leader sequence. Stippled lines show SUR1 sequences used in the recombinant proteins
whose names are indicated on the right. Arrows indicate sites on SUR1 used for generation of a SUR1 deletion mutant. White boxes (A and
B) show the location of Walker A and B motifs that can form nucleotide binding sites in each putative cytosolic NBD (NBD1 and NBD2).
The identities and positions in intact SUR1 of the N- and C-terminal aa of each fragment are indicated. All constructs contain a C-terminal
His6 tag.
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(line 5). This indicates that the conformation of the glibencla-
mide binding site in recombinant proteins is similar to its
conformation in native SUR1.
Consistent with our previous observations [31], deletion of
NBD2 from the COOH-terminus of SUR1 (SUR1tr) had no
signi¢cant e¡ect on glibenclamide binding (Table 1, line 6).
Further deletion of ¢ve TM domains of TMD0 from the
NH2-terminus of SUR1tr (SUR1tr1) also had no signi¢cant
e¡ect on glibenclamide binding (Table 1, line 7) whereas dele-
tion of cytosolic loop CL3 between TMD0 and TMD1
(SUR1tr2) abolished binding (Table 1, line 8). This ¢nding
indicates a signi¢cant role for CL3 in glibenclamide binding.
Investigation of glibenclamide binding with variants of
SUR1tr1 with two deleted adjacent TM domains from
TMD1 showed that only in the case of deletion of TM9
and TM10 (SUR1tr1v9/10; Table 1, line 12) signi¢cant bind-
ing was retained. This ¢nding indicates that deletion of TM9
and TM10 does not signi¢cantly change the conformation of
SUR1 and the cytosolic loop between these domains is thus
not essential for glibenclamide binding. Other deletion mu-
tants used in the present study (SUR1tr1v6/7 with deletion
of TM6 and TM7 (Table 1, line 9), SUR1tr1v7/8 with dele-
tion of TM7 and TM8 (Table 1, line 10), SUR1tr1v8/9 with
deletion of TM8 and TM9 (Table 1, line 11) and SUR1tr1v10/
11 with deletion of TM10 and TM11 (Table 1, line 13)) re-
tained no signi¢cant glibenclamide binding.
We have previously demonstrated [26,31] that when SUR1
is divided between NBD1 and TM12 and either the N-termi-
nal SUR1 half-molecule (NSUR2), or the C-terminal half-
molecule (CSUR2) expressed separately in S. frugiperda cells,
glibenclamide binding is not signi¢cantly greater than in cells
infected with parent baculovirus. However, as con¢rmed here
(Table 1, line 1), in cells co-infected with both halves of SUR1
a substantial increase of glibenclamide binding activity is ob-
served. The present study further demonstrates that glibencla-
mide binding activity is also retained when the C-terminal
half-molecule (CSUR2) is co-expressed with an N-terminal
SUR1 half-molecule (NSUR21) in which the TMD0 region
is deleted from the COOH end (NSUR21+CSUR2, Table 1,
line 2). This indicates that TMD0 is not essential either for
glibenclamide binding or for self-assembly of SUR1 half-mol-
Fig. 2. Western blot of lysed S. frugiperda insect cells expressing
SUR1 fragments with anti-NBD1 antisera. Lanes: 1 ^ mock-infected
cells ; 2 ^ NSUR2; 3 ^ NSUR21; 4 ^ NSUR21G; 5 ^ NSUR21v9/
10; 6 ^ NSUR22; 7 ^ NSUR22G; 8 ^ SUR1tr; 9 ^ SUR1tr1; 10 ^
SUR1tr2; 11 ^ SUR1tr1v6/7; 12 ^ SUR1tr1v7/8; 13 ^ SUR1tr1v8/
9; 14 ^ SUR1tr1v9/10; 15 ^ SUR1tr1v10/11.
Fig. 3. Fluorescent microscopy of Sf9 insect cells infected with recombinant baculoviruses. Insect cells expressing: A ^ GFP; B ^ NSUR21G;
C ^ NSUR22G.
Table 1
Glibenclamide binding to insect cells expressed di¡erent recombinant
proteins
Line Expressed proteins Kd (nm) Bmax (binding sites/
cellU103)
1 NSUR2+CSUR2 1.43 þ 0.51 863 þ 41
2 NSUR21+CSUR2 1.92 þ 0.52 546 þ 43
3 NSUR22+CSUR2 NB NB
4 NSUR21v9/10+CSUR2 1.37 þ 0.32 383 þ 51
5 SUR1 1.81 þ 0.53 2990 þ 95
6 SUR1tr 1.22 þ 0.41 2201 þ 80
7 SUR1tr1 1.57 þ 0.62 2070 þ 260
8 SUR1tr2 NB NB
9 SUR1tr1v6/7 NB NB
10 SUR1tr1v7/8 NB NB
11 SUR1tr1v8/9 NB NB
12 SUR1tr1v9/10 1.54 þ 0.44 2129 þ 235
13 SUR1tr1v10/11 NB NB
14 SUR1-17 1.61 þ 0.43 2340 þ 160
15 SUR1-16 1.25 þ 0.57 2580 þ 190
16 SUR1-16a NB NB
17 NSUR2+CSUR3 1.38 þ 0.52 253 þ 41
18 NSUR2+CSUR3tr 1.83 þ 0.57 524 þ 58
19 NSUR2+CSUR3-17 1.23 þ 0.41 210 þ 25
20 NSUR2+CSUR3-16 NB NB
21 NSUR2+CSUR3atr 1.73 þ 0.64 590 þ 61
Sf21 cells expressing the recombinant proteins indicated were incu-
bated at RT for 30 min with di¡erent concentrations of
[3H]glibenclamide (0.2^10 nM). The incubation was stopped by rap-
id separation on Whatman GF/C ¢lters soaked in PBS for 30 min
beforehand. Filters were washed and speci¢c binding determined.
The dissociation constant, Kd, and the number of glibenclamide
binding sites per cell (Bmax) were estimated as described in Section 2.
NB: no detectable speci¢c binding.
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ecules. Further deletion of the cytosolic loop (CL3) between
TMD0 and TMD1 from NSUR21 (NSUR22) resulted in loss
of glibenclamide binding activity when NSUR22 was co-ex-
pressed with CSUR2 (Table 1, line 3), con¢rming an essential
role for CL3 in glibenclamide binding. The deletion variant of
NSUR21 where TM9 and TM10 were removed (NSUR21v9/
10) demonstrated signi¢cant glibenclamide binding when co-
expressed with CSUR2 (Table 1, line 4). This ¢nding is con-
sistent with the tolerance of SUR1 conformation to such a
mutation, as demonstrated above, and con¢rms that TM9 and
TM10 do not take part in self-assembly of SUR1 half-mole-
cules.
As mentioned above, deletion of NBD2 from the COOH-
terminus of SUR1 (SUR1tr) had no signi¢cant e¡ect on gli-
benclamide binding (Table 1, line 6). Further deletion of
TM17 (SUR1-17, Table 1, line 14) or TM17 and TM16
(SUR1-16, Table 1, line 15) had no signi¢cant e¡ect on gli-
benclamide binding, whereas further deletion of CL8 from the
COOH-terminus of SUR1 (SUR1-16a, Table 1, line 16) abol-
ished binding. This ¢nding re£ects the importance of CL8 for
glibenclamide binding.
Investigation of glibenclamide binding after co-expression
of NSUR2 with di¡erent truncated variants of CSUR3 shows
that: (i) deletion of NBD2 from the COOH end leads to some
increase of glibenclamide binding activity, which may be due
to facilitated folding (CSUR3tr, Table 1, line 18); (ii) further
deletion of TM17 does not prevent glibenclamide binding
(CSUR3-17, Table 1, line 19); (iii) further deletion of TM16
abolishes binding (CSUR3-16, Table 1, line 20). Taking into
account that deletion from the whole SUR1 molecule of either
TM17 or TM16 and TM17 together had no signi¢cant in£u-
ence on glibenclamide binding, we conclude that TM16 is
Fig. 4. A: Model of the L-cell KATP channel. The ¢gure shows a cross-sectional view of the TM topology of the L-cell KATP channel. The cur-
rent model is based on our previously published model of the L-cell KATP channel [31]. Additional features of the model based on the present
study are: (i) TMD0 is not essential for assembly; (ii) deletion of TM9 and TM10 does not a¡ect assembly; (iii) TM16 is essential for self-as-
sembly of part molecules. The location of TM sequences in the model also re£ects TM12^Kir6.2 interaction and the ¢nding that TM12 and
TM13 are not essential for self-assembly [31]. The model indicates the suggested proximity of cytosolic loops between TM5/TM6 (CL3) and
TM15/TM16 (CL8), that together form the glibenclamide binding site. The model also shows the presumed internal location of Kir6.2 to form
the permeation pathway. B: Model of the truncated and deleted variants of SUR1. The ¢gure provides cross-sectional views within the mem-
brane and illustrates how formation of the glibenclamide binding site could be a¡ected by (i) truncation of SUR1; and (ii) deletion of pairs of
TM sequences in TMD1 which alters the distance between CL3 and CL8.
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essential for molecular assembly of the SUR1 half-molecules.
Deletion of the cytosolic loop between TM13 and TM14
(CL7) from the NH2-terminus of CSURtr has no signi¢cant
e¡ect on glibenclamide binding (CSUR3atr, Table 1, line 21),
indicating a lack of involvement of CL7 in glibenclamide
binding. Combining data from COOH- and NH2-termini
truncation we can conclude that CL8 is the only cytosolic
structure of SUR1 needed for formation of the C-terminal
component of the glibenclamide binding site.
4. Discussion
The ¢rst set of ¢ve TM domains (TMD0) of SUR1 is not
present in the majority of ABC proteins and as we show here
does not take part either in SUR1 assembly or in formation of
the glibenclamide binding site. This is consistent both with
our model of KATP channel structure ([31], Fig. 4A) and
with that proposed by Schwappach et al. [23].
Previously, by di¡erent approaches, it was demonstrated
that formation of the SUR1 high a⁄nity glibenclamide bind-
ing site needs the presence of two distinct parts of SUR1
[25,26]. The cytosolic loop between TM15 and TM16 (CL8)
is now shown here to be the only cytosolic structure of SUR1
taking part in formation of the C-proximal part of the gliben-
clamide binding site. The presence of only this loop in a
C-terminal half-molecule of SUR1 leads to restoration of gli-
benclamide binding activity after co-expression with an
N-terminal half-molecule. Deletion of this loop abolishes gli-
benclamide binding. This is consistent with previous data that
mutation in this loop (Ser to Tyr at position 1238) leads to a
marked decrease of glibenclamide a⁄nity [25,31]. Our data
now demonstrate a signi¢cant role for the cytosolic loop be-
tween TMD0 and TMD1 (CL3) in formation of the N-prox-
imal part of the glibenclamide binding site. Deletion of this
loop (from Pro207 to Ala294) leads to loss of glibenclamide
binding activity.
It is important for our interpretation of the data to exclude
the possibility that a failure of SUR1 fragments to target
correctly to the plasma membrane accounts for the negative
results when we measure glibenclamide binding in our intact
cells (Table 1, lines 3, 8^11, 16, 20). However we do not
believe that any of these negative data can be attributed to
this mechanism for the following reasons. Firstly, we have
shown clearly using GFP-tagged proteins that NSUR21 and
NSUR22, which lack a native leader sequence, do correctly
insert into the plasma membrane. These data taken together
with those of line 2 of Table 1 show that NSUR22 and
CSUR2 have reached the membrane. Secondly, since SURtr2
has the same 5P-sequence as NSUR22 we believe it is safe to
assume membrane targeting for this construct. Thirdly, the
deletion variants have the same 5P-sequence as SURtr1 which
our data demonstrate to be capable of correctly targeting the
membrane and folding (Table 1, line 6), and the deleted se-
quences do not contain any known targeting signals.
Fourthly, SUR1-16a contains the same leader sequence as
native SUR1 and therefore should be correctly targeted. Fi-
nally, we have con¢rmed by using a GFP-tagged version that
CSUR3-16 correctly targets the plasma membrane (data not
shown).
We therefore interpret the ¢ndings in terms of the model of
the KATP channel shown in Fig. 4. The model suggests (Fig.
4A) that CL3 and CL8 despite their separate location in the
primary structure of SUR1 can be in close proximity in the
three-dimensional structure. Deletion of any two of the TM
sequences from TMD1 (except TM9 plus TM10) leads to a
change in distance between CL3 and CL8 (Fig. 4B) that could
explain loss of glibenclamide binding activity in the corre-
sponding recombinant proteins. TM8 and TM11 could be
located proximately such that deletion of TM9 and TM10
does not in£uence glibenclamide binding or SUR1 assembly
(Fig. 4B).
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